Teva profit beats forecasts, raises 2026 revenue estimates
TEVA•TEVA•TEVA•TEVA•Teva reported third-quarter adjusted earnings of 86 cents per share, above forecasts of 72 cents, on revenue of $4.4 billion. It raised its 2026 revenue forecast to $16.7 billion-$17 billion, citing higher projections for branded drugs.
Teva reported third-quarter adjusted earnings of 86 cents per share, up from 78 cents a year earlier and above analysts’ forecast of 72 cents. Revenue fell 2% to $4.4 billion as generic-drug sales declined 16%; analysts had forecast revenue of $4.22 billion.
The company raised its 2026 revenue forecast to $16.7 billion-$17 billion, citing higher sales projections for Austedo, Ajovy and Uzedy. Austedo sales rose 21% to $751 million, Ajovy sales jumped 61% to $269 million, and Uzedy sales doubled to $85 million. CEO Richard Francis said he expects continued growth in 2027 led by branded drugs, while generic drugs are also expected to grow as biosimilars reach the market.
